BCL2 and hepatocellular carcinoma: Phosphorylation of ERK1/2 has been reported to activate pro-survival pathways inducing anti-apoptotic proteins such as BCL2, and downregulation of p53 in breast, cervical, and hepatocellular carcinoma [30,52].